Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The checkmate 016 study

Journal of Clinical Oncology

Volumn 35, Issue 34, 2017, Pages 3851-3858

  Hammers, Hans J ^a   Plimack, Elizabeth R ^b   Infante, Jeffrey R ^c   Rini, Brian I ^d   McDermott, David F ^e   Lewis, Lionel D ^f   Voss, Martin H ^g   Sharma, Padmanee ^h   Pal, Sumanta K ⁱ   Abdul Razak, Albiruni R ^j   Kollmannsberger, Christian ^k   Heng, Daniel Y C ^l   Spratlin, Jennifer ^m   Brent McHenry, M ⁿ   Amin, Asim ^o  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^j PRINCESS MARGARET HOSPITAL   (Canada)

^k BRITISH COLUMBIA CANCER AGENCY   (Canada)

^l UNIVERSITY OF CALGARY   (Canada)

^m UNIVERSITY OF ALBERTA   (Canada)

ⁿ BRISTOL MYERS SQUIBB   (United States)

^o LEVINE CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; CREATININE; INFLIXIMAB; IPILIMUMAB; MYCOPHENOLIC ACID; NIVOLUMAB; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CHILL; COLITIS; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTHYROIDISM; KIDNEY DISEASE; KIDNEY METASTASIS; LIVER DISEASE; LUNG DISEASE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SIDE EFFECT; SKIN DISEASE; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; KIDNEY TUMOR; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RENAL CELL CARCINOMA; RISK ASSESSMENT; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; IPILIMUMAB; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE;

EID: 85032035687     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.72.1985     Document Type: Article

References (27)

1. Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-E386, 2015
2. Cairns P: Renal cell carcinoma. Cancer Bio-mark 9:461-473, 2010
3. Gupta K, Miller JD, Li JZ, et al: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev 34:193-205, 2008
4. Bedke J, Gauler T, Grunwald V, et al: Systemic therapy in metastatic renal cell carcinoma. World J Urol, 35:179-188, 2017
5. Koneru R, Hotte SJ: Role of cytokine therapy for renal cell carcinoma in the era of targeted agents. Curr Oncol 16:S40-S44, 2009 (suppl 1)
6. Fisher R, Gore M, Larkin J: Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol 23:38-45, 2013
7. Schmidinger M: Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl 11:172-191, 2013
8. Albiges L, Chamming’s F, Duclos B, et al: Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 23:1943-1953, 2012
9. Escudier B: Emerging immunotherapies for renal cell carcinoma. Ann Oncol 23:viii35-viii40, 2012 (suppl 8)
10. Raman R, Vaena D: Immunotherapy in metastatic renal cell carcinoma: A comprehensive review. BioMed Res Int 2015:367354, 2015
11. Opdivo (nivolumab) injection [prescribing information]. Princeton, NJ, Bristol-Myers Squibb, 2016
12. Buchbinder EI, Desai A: CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. Am J Clin Oncol 39:98-106, 2016
13. Motzer RJ, Escudier B, McDermott DF, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803-1813, 2015
14. Motzer RJ, Rini BI, McDermott DF, et al: Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol 33: 1430-1437, 2015
15. Cella D, Grünwald V, Nathan P, et al: Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: A randomised, open-label, phase 3 trial. Lancet Oncol 17:994-1003, 2016
16. Yervoy (ipilimumab) injection [prescribing information]. Princeton, NJ, Bristol-Myers Squibb, 2015
17. Chambers CA, Kuhns MS, Egen JG, et al: CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19:565-594, 2001
18. Wolchok JD, Saenger Y: The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13:2-9, 2008 (suppl 4)
19. Yang JC, Hughes M, Kammula U, et al: Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30:825-830, 2007
20. Antonia SJ, López-Martin JA, Bendell J, et al: Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial. Lancet Oncol 17:883-895, 2016
21. Hellman MD, Gettinger SN, Goldman JW, et al: CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. J Clin Oncol 34, 2016 (suppl; abstr 3001)
22. Larkin J, Hodi FS, Wolchok JD: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1270-1271, 2015
23. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013
24. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
25. Schag CC, Heinrich RL, Ganz PA: Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncol 2:187-193, 1984
26. Clopper CJ, Pearson ES: The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404-413, 1934
27. Greenwood M: The natural duration of cancer. Rep Public Health Med Subj (Lond) 33:1-26, 1926